Department of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyotanabe, Kyoto 610-0395, Japan.
Mol Pharm. 2024 Nov 4;21(11):5736-5748. doi: 10.1021/acs.molpharmaceut.4c00729. Epub 2024 Oct 7.
Pharmacokinetic (PK) elucidation of polymeric micelles delivering anticancer drugs is crucial for accurate antitumor PK-pharmacodynamic (PK-PD) simulations. Particularly, establishing a methodology to quantify the tumor inflow and outflow of anticancer drugs encapsulated in polymeric micelles is an essential challenge. General tumor biodistribution experiments are disadvantageous in that inflow quantification is easy, but outflow quantification is challenging. We addressed this issue by proposing a quantification method that combines a tissue-isolated tumor perfusion system with microdialysis. This method aims to determine tumoral drug inflow and outflow by quantifying the drugs released from the polymeric micelles via a tumor-embedded microdialysis probe and perfusate, respectively. Furthermore, we evaluated the feasibility of this method by perfusing pH-sensitive polyethylene glycol-poly(aspartate-hydrazone-doxorubicin/phenylalanine)n (PPDF-Hyd-DOX) in a tissue-isolated tumor perfusion system, and we quantified tumor inflow and outflow released DOX. Based on the quantitative results, we performed compartmental analyses by incorporating the gamma-distributed delay function and calculated the PK rate constants. These parameters were input into a tumor-bearing rat compartment model for ex vivo-in vivo extrapolation (EVIVE) of the rat plasma PPDF-Hyd-DOX concentrations and simulated intratumorally released DOX concentrations. The simulation profiles demonstrated a good fit with the Walker 256 intratumoral released DOX concentration profiles previously reported. This EVIVE-PK model was coupled with the threshold natural-growth tumor PD model, and PK-PD analysis was performed. This model exhibited a better fit to the tumor weight profile of Walker 256-bearing rats treated with PPDF-Hyd-DOX than that of our previously reported PK-PD model. Thus, EVIVE, based on a tissue-isolated tumor perfusion system with microdialysis, is a promising approach for the PK-PD simulation of polymeric micelle anticancer therapy.
阐明递药聚合物胶束的药代动力学(PK)对于准确的抗肿瘤 PK-药效动力学(PK-PD)模拟至关重要。特别是,建立一种量化包裹在聚合物胶束中的抗癌药物的肿瘤内流入和流出的方法是一个重要的挑战。一般的肿瘤生物分布实验有一个缺点,即流入的定量很容易,但流出的定量却很困难。我们通过提出一种将组织隔离的肿瘤灌注系统与微透析相结合的定量方法来解决这个问题。该方法旨在通过分别定量从聚合物胶束中释放的药物来确定肿瘤内药物的流入和流出。此外,我们通过在组织隔离的肿瘤灌注系统中灌注 pH 敏感的聚乙二醇-聚(天冬氨酸-腙-阿霉素/苯丙氨酸)n(PPDF-Hyd-DOX)来评估该方法的可行性,并定量分析了肿瘤内流出的 DOX。基于定量结果,我们通过纳入伽马分布延迟函数进行了房室分析,并计算了 PK 速率常数。这些参数被输入到荷瘤大鼠房室模型中,用于大鼠血浆 PPDF-Hyd-DOX 浓度的离体-体内外推(EVIVE)和模拟肿瘤内释放的 DOX 浓度。模拟曲线与之前报道的 Walker 256 肿瘤内释放 DOX 浓度曲线吻合较好。该 EVIVE-PK 模型与阈值自然生长肿瘤 PD 模型相结合进行 PK-PD 分析。与我们之前报道的 PK-PD 模型相比,该模型对 PPDF-Hyd-DOX 治疗 Walker 256 荷瘤大鼠的肿瘤重量曲线的拟合更好。因此,基于组织隔离的肿瘤灌注系统与微透析的 EVIVE 是聚合物胶束抗癌治疗 PK-PD 模拟的一种很有前途的方法。